1/28/2013

The FDA has granted Takeda Pharmaceuticals approval for its type 2 diabetes drug alogliptin as a standalone medication and as an add-on to metformin in the company's Kazano formulation and with pioglitazone under the name Oseni. Alogliptin alone will be branded as Nesina.

Full Story:
Reuters

Related Summaries